KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.75

AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients.

Todd P Knutson, Bin Luo, Anna Kobilka, Jacqueline Lyman, Siyuan Guo, Sarah A Munro, Yingming Li, Rakesh Heer, Luke Gaughan, Michael J Morris, Himisha Beltran, Charles J Ryan, Emmanuel S Antonarakis, Andrew J Armstrong, Susan Halabi, Scott M Dehm

Nat Commun 15(1) 10648

PMID39663356
PMCIDPMC11634963
DOI10.1038/s41467-024-54847-1
发表日期2024-12-11
入排依据:The record describes a secondary, biomarker-focused analysis (ctDNA detection) within a Phase III randomized trial. While it references the trial's drug intervention and OS endpoint, it is not the original primary efficacy report comparing intervention arms. It is a correlative/prognostic sub-study, which falls under the excluded 'post-hoc subgroup, biomarker-only' category for adjudication of primary trial KM data.
摘要

摘要

Circulating tumor DNA (ctDNA) in plasma cell free DNA (cfDNA) of cancer patients is associated with poor prognosis, but is challenging to detect from low plasma volumes. In metastatic castration-resistant prostate cancer (mCRPC), ctDNA assays are needed to prognosticate outcomes of patients treated with androgen receptor (AR) inhibitors. We develop a custom targeted cfDNA sequencing assay, named AR-ctDETECT, to detect ctDNA in limiting plasma cfDNA available from mCRPC patients in the Alliance A031201 randomized phase 3 trial of enzalutamide with or without abiraterone. Of 776 patients, 59% are ctDNA-positive, with 26% having high ctDNA aneuploidy and 33% having low ctDNA aneuploidy but displaying AR gain or structural rearrangement, MYC/MYCN gain, or a pathogenic mutation. ctDNA-positive patients have significantly worse median overall survival than ctDNA-negative patients (29.0 months vs. 47.4 months, respectively). Here, we show that mCRPC patients identified as ctDNA-positive using the AR-ctDETECT assay have poor survival despite treatment with potent AR inhibitors in a phase 3 trial.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。